Maria Martínez-Iniesta

Maria Martínez-Iniesta

Auto-generated profile, based on publicly available information

Maria Martínez-Iniesta

Catalan Institute of Oncology (ICO)

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMarie-Julie Nokin
Marie-Julie Nokin
AMAlessia Mira
Alessia Mira
EPEnrico Patrucco
Enrico Patrucco
BRBiagio Ricciuti
Biagio Ricciuti
SCSophie Cousin
Sophie Cousin
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
Selective KRASG12C inhibitors have been developed to covalently lock the oncogene in the inactive GDP-bound state. Two of these molecules, sotorasib and adagrasib, are approved for the treatment of adult patients with KRASG12C-mutated previously treated advanced non-small cell lung cancer. Drug treatment imposes selective pressures leading to the outgrowth of drug-resistant variants. Mass sequencing from patients’ biopsies identified a number of acquired KRAS mutations -both in cis and in trans- in resistant tumors. We demonstrate here that disease progression in vivo can also occur due to adaptive mechanisms and increased KRAS-GTP loading. Using the preclinical tool tri-complex KRASG12C-selective covalent inhibitor, RMC-4998 (also known as RM-029), that targets the active GTP-bound (ON) state of the oncogene, we provide a proof-of-concept that the clinical stage KRASG12C(ON) inhibitor RMC-6291 alone or in combination with KRASG12C(OFF) drugs can be an alternative potential therapeutic strategy to circumvent resistance due to increased KRAS-GTP loading.

14 November 2022 in Advanced Science
Verified
Journal Article
Open access
LDLaura Devis‐Jauregui
Laura Devis‐Jauregui
AVAugust Vidal
August Vidal
LPLaura Plata‐Peña
Laura Plata‐Peña
MSMaria Santacana
Maria Santacana
SGSandra García-Mulero
Sandra García-Mulero
DLDavid Llobet-Navas
David Llobet-Navas
Clinical management of endometrial cancer (EC) is handicapped by the limited availability of second line treatments and bona fide molecular biomarkers to predict recurrence. These limitations have hampered the treatment of these patients, whose survival rates have not improved over the last four decades. The advent of coordinated studies such as The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma (TCGA_UCEC) has partially solved this issue, but the lack of proper experimental systems still represents a bottleneck that precludes translational studies from successful clinical testing in EC patients. Within this context, the first study reporting the generation of a collection of endometrioid‐EC‐patient‐derived orthoxenograft (PDOX) mouse models is presented that is believed to overcome these experimental constraints and pave the way toward state‐of‐the‐art precision medicine in EC. The collection of primary tumors and derived PDOXs is characterized through an integrative approach based on transcriptomics, mutational profiles, and morphological analysis; and it is demonstrated that EC tumors engrafted in the mouse uterus retain the main molecular and morphological features from analogous tumor donors. Finally, the molecular properties of these tumors are harnessed to assess the therapeutic potential of trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor with growing interest in EC, using patient‐derived organotypic multicellular tumor spheroids and in vivo experiments.

5 May 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JFJuana Fernández-Rodríguez
Juana Fernández-Rodríguez
ECEdgar Creus-Bachiller
Edgar Creus-Bachiller
XZXiaohu Zhang
Xiaohu Zhang
MMMaria Martínez-Iniesta
Maria Martínez-Iniesta
SOSara Ortega-Bertran
Sara Ortega-Bertran
Conxi LázaroConxi Lázaro
Conxi Lázaro
Malignant peripheral nerve sheath tumors (MPNST) are soft-tissue sarcomas that are the leading cause of mortality in patients with Neurofibromatosis type 1 (NF1). Single chemotherapeutic agents have shown response rates ranging from 18% to 44% in clinical trials, so there is still a high medical need to identify chemotherapeutic combination treatments that improve clinical prognosis and outcome. We screened a collection of compounds from the NCATS Mechanism Interrogation PlatE (MIPE) library in three MPNST cell lines, using cell viability and apoptosis assays. We then tested whether compounds that were active as single agents were synergistic when screened as pairwise combinations. Synergistic combinations in vitro were further evaluated in patient-derived orthotopic xenograft/orthoxenograft (PDOX) athymic models engrafted with primary MPNST matching with their paired primary-derived cell line where synergism was observed. The high-throughput screening identified 21 synergistic combinations, from which four exhibited potent synergies in a broad panel of MPNST cell lines. One of the combinations, MK-1775 with Doxorubicin, significantly reduced tumor growth in a sporadic PDOX model (MPNST-SP-01; sevenfold) and in an NF1-PDOX model (MPNST-NF1–09; fourfold) and presented greater effects in TP53 mutated MPNST cell lines. The other three combinations, all involving Panobinostat (combined with NVP-BGT226, Torin 2, or Carfilzomib), did not reduce the tumor volume in vivo at noncytotoxic doses. Our results support the utility of our screening platform of in vitro and in vivo models to explore new therapeutic approaches for MPNSTs and identified that combination MK-1775 with Doxorubicin could be a good pharmacologic option for the treatment of these tumors.

1 February 2016 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
EMElisabet Matas
Elisabet Matas
LBLaura Bau
Laura Bau
MMMaría Martínez-Iniesta
María Martínez-Iniesta
LRLucía Romero-Pinel
Lucía Romero-Pinel
MMM. Alba Mañé-Martínez
M. Alba Mañé-Martínez
SMSergio Martínez-Yélamos
Sergio Martínez-Yélamos

4 October 2025 in European Journal of Cancer
Verified
Journal Article
Open access
DRDeepthi Ramesh-Kumar
Deepthi Ramesh-Kumar
ACAnais Sanchez Castillo
Anais Sanchez Castillo
MSMarta Soler
Marta Soler
JMJuan Francisco Martin-Tejera
Juan Francisco Martin-Tejera
COCristina Oliveira-Mateos
Cristina Oliveira-Mateos
LFLourdes Farre
Lourdes Farre
The RPSAP52 pseudogene is transcribed in the opposite direction to the oncofetal gene HMGA2 and is reexpressed in various human cancers. Here, we investigate the impact of RPSAP52 in ovarian cancer (OC) and explore the potential therapeutic application of GapmeR antisense oligonucleotides against RPSAP52 in preclinical models. RPSAP52 and HMGA2 expression were investigated in TCGA for OC and further explored in a panel of orthotopic PDXs and commercial cell lines by RT-qPCR. The Kaplan-Meier method was used to estimate survival associated with RPSAP52 expression in a dataset within the OC TCGA cohort. The effect of specific silencing of RPSAP52 on tumor growth in vitro and in vivo was evaluated by lentiviral-mediated depletion and antisense LNA GapmeRs against RPSAP52. The pseudogene RPSAP52 was overexpressed in epithelial OC in both patient samples and OC preclinical models coinciding with the overexpression of HMGA2. Elevated expression levels of RPSAP52 in the early stages of OC were associated with poorer clinical outcomes and could stratify patients in stages I and II. The specific depletion of RPSAP52 led to a reduction in OC tumor growth in vitro and in vivo. Furthermore, the treatment with antisense LNA GapmeRs against RPSAP52 showed significant antitumoral effect in OC cell lines and in a PDOX model (without evident toxicity). Our findings demonstrate that RPSAP52 displays pro-growth features in OC, underscoring the significance of pseudogenes in cancer pathophysiology. This pseudogene has potential utility as therapeutic target in OC and as valuable prognostic biomarker for the early stages of this disease.

3 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
DADaniel Alvarez-Villanueva
Daniel Alvarez-Villanueva
MMMaría Maqueda
María Maqueda
DHDina Harti
Dina Harti
ECEric Canton
Eric Canton
EAEvelyn Andrades
Evelyn Andrades
Lluis EspinosaLluis Espinosa
Lluis Espinosa
Colorectal cancer (CRC) frequently develops aggressive metastatic disease, yet the cellular features that enable dissemination remain poorly defined. IKKα, a kinase traditionally linked to stress and inflammatory signaling, is increasingly recognized for broader functions in cancer. Here, we show that loss of IKKα unexpectedly promotes metastasis in CRC. Using patient-derived organoids, we find that genetic or pharmacological inhibition of IKKα stabilizes tight-junction components, leading to the emergence of compact epithelial clusters with a heightened ability to spread and colonize the liver. Single-cell transcriptomics reveals expansion of a CDH17⁺/CLDN2⁺ epithelial subpopulation that dominates metastatic lesions, a finding validated by tissue staining. Remarkably, disrupting CLDN2 completely eliminates the metastatic advantage caused by IKKα loss. These results identify a metastasis-competent epithelial state driven by tight-junction remodeling and uncover a vulnerable node that may be exploited therapeutically in aggressive colorectal cancer.